September 21st 2023
September 18th 2023
New CMS Models Target Transformation to Address Need for Health Equity
September 21st 2023"CMS cannot do this alone. We have to do this in partnership. So really thinking about providers and beneficiaries and how we do this together," Ellen Lukens, MPH, Center for Medicare and Medicaid Innovation, explained.
Panelists Discuss Insurance Coverage of Opill, OTC Contraceptives During KFF Webinar
September 21st 2023Laurie Sobel, the associate director for women’s health policy at KFF, moderated a panel discussion with Christine Gilroy, MD, MPH; Victoria Nichols, MPH; and Don Downing, RPh, about insurance coverage of FDA-approved Opill and other OTC contraceptives.
Tailored EHR Alerts Fail to Improve Acute HF Medication Prescription at Discharge
September 21st 2023A tailored electronic health record (EHR) alert system did not significantly increase the prescription of guideline-directed medical therapies (GDMT) at hospital discharge for patients with acute heart failure (AHF).
What We’re Reading: Free COVID-19 Tests; Vaccine Distrust; FDA Rejects Epinephrine Spray
The Biden administration will once again provide free COVID-19 tests for Americans; vaccine skepticism exists on both sides of the presidential race, concerning health officials; the FDA denied an application for the first nasal spray to treat allergic reactions, including anaphylaxis.
Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL
Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
First-Line Sacituzumab Govitecan Plus Pembrolizumab Shows Promising Early Activity in NSCLC
In a preliminary analysis of the phase 2 EVOKE-02 trial, the investigational combination regimen showed an objective response rate of 56% in previously untreated patients with metastatic non–small cell lung cancer (NSCLC).
Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis
In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
Most people don’t know they have hypertension, and a new recommendation advises that pregnant women should be screened for blood pressure disorders at every appointment; patients in primary care face long wait times, which may be due to physician incentives under value-based payments; a lawsuit in New Jersey targets the residency requirement to allow aid in dying for those out of state.
Dr Konstantinos Leventakos Highlights the Challenge of Treatment Metastatic SCLC
Small cell lung cancer (SCLC) needs to be treated quickly once diagnosed, said Konstantinos Leventakos, MD, PhD, assistant professor of oncology and medicine, Mayo Clinic, Rochester, Minnesota.
Adalimumab Plus Surgery Delivers Better Outcomes Than Adalimumab Alone for HS
September 19th 2023Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with adalimumab alone.